Vizsgálati helyszín
Hyogo Medical University Hospital
Nishinomiya, Hyōgo 663-8501, JapánMég nincs intézményhez kötve
Az itteni vizsgálatok
Miről szól a helyszín 15 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis7 vizsgálat
- 2. fázis6 vizsgálat
- 1/2. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Toboroz12 vizsgálat
- Fut, nem toboroz3 vizsgálat
- Fő szponzor
- Bristol-Myers Squibb2 vizsgálat
- Eli Lilly and Company2 vizsgálat
- Janssen Research & Development, LLC2 vizsgálat
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company2 vizsgálat
- BioNTech SE1 vizsgálat
- és még 6
Futó vizsgálatok
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014· 2. fázis· Eisai Co., Ltd.· Forrás
Toboroz
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· 2. fázis· Eli Lilly and Company· Forrás
Contact: Shinichiro Shinzaki (principal investigator)
Toboroz
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Takashi Kijima, Site 0154
Toboroz
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Takashi Kijima, Site 0251
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Contact: Hirayuki Enomoto (principal investigator)
Toboroz
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479· 3. fázis· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás
Contact: Satoshi Yoshihara, Site 0087
Toboroz
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· 2/3. fázis· BioNTech SE· Forrás
Fut, nem toboroz
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814· 1/2. fázis· NS Pharma, Inc.· Forrás
Toboroz
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226· 2. fázis· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás
Contact: Satoshi Yoshihara, Site 0058
Fut, nem toboroz
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
NCT06318286· 2. fázis· Hyogo Medical University· Forrás
Toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461· 2. fázis· Takeda· Forrás
Contact: Shinichiro Shinzaki (principal investigator)
Fut, nem toboroz
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806· 3. fázis· Celgene· Forrás
Toboroz
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT05287126· 2. fázis· Pfizer· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek